Relay Therapeutics (RLAY) Long-Term Investments (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Long-Term Investments of $437.5 million for Q1 2026, down 29.07% year-over-year from $616.8 million in Q1 2025, and down 7.02% quarter-over-quarter from $470.5 million in Q4 2025.
Relay Therapeutics (RLAY) Long-Term Investments (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Long-Term Investments for 8 consecutive years, with $437.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments fell 29.07% year-over-year to $437.5 million; the TTM figure through Mar 2026 stood at $437.5 million (down 29.07% YoY), while the FY2025 annual figure was $470.5 million, down 28.39% from the prior year.
- Long-Term Investments eased to $437.5 million in Q1 2026 per RLAY's latest filing, from $470.5 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $847.1 million in Q4 2022 and bottomed at $437.5 million in Q1 2026.
- Historically, Long-Term Investments has averaged $640.6 million across 5 years, with a median of $657.0 million in 2024.
- Annual changes were most pronounced in 2022 — Long-Term Investments soared 80.22% — and 2026, when it slipped 29.07%.
- Relay Therapeutics' Long-Term Investments stood at $847.1 million in 2022, then declined by 28.42% to $606.4 million in 2023, then increased by 8.36% to $657.0 million in 2024, then slipped by 28.39% to $470.5 million in 2025, then dropped by 7.02% to $437.5 million in 2026.
- Business Quant data shows RLAY's Long-Term Investments at $437.5 million in Q1 2026, $470.5 million in Q4 2025, and $504.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 789.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 789.75 Mn |
| Mar 31, 2026 | 437.48 Mn |
| Dec 31, 2025 | 470.50 Mn |
| Sep 30, 2025 | 504.87 Mn |
| Jun 30, 2025 | 542.83 Mn |
| Mar 31, 2025 | 616.81 Mn |
| Dec 31, 2024 | 657.04 Mn |
| Sep 30, 2024 | 687.25 Mn |
| Jun 30, 2024 | 554.29 Mn |
| Mar 31, 2024 | 596.74 Mn |
| Dec 31, 2023 | 606.35 Mn |
| Sep 30, 2023 | 659.29 Mn |
| Jun 30, 2023 | 725.67 Mn |
| Mar 31, 2023 | 776.53 Mn |
| Dec 31, 2022 | 847.12 Mn |
| Sep 30, 2022 | 699.15 Mn |
| Jun 30, 2022 | 730.25 Mn |
| Mar 31, 2022 | 778.73 Mn |
| Dec 31, 2021 | 677.95 Mn |
| Sep 30, 2021 | 387.95 Mn |